What To Know
- Existing CardioLabs customers will retain access to the full suite of cardiac monitoring services previously available to them including Mobile Cardiac Telemetry, Cardiac Event Monitoring, Extended Holter and Holter monitoring.
- “The acquisition of CardioLabs sets AliveCor on a course to becoming the premier provider of end-to-end cardiac diagnostic support,”.
AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology and services, today announced that it has acquired the independent diagnostic testing facility (IDTF) CardioLabs, a leading monitoring, and cardiac diagnostic service provider.
The acquisition is a cornerstone of AliveCor’s mission to extend its comprehensive cardiological services to patients who are prescribed monitoring devices by their healthcare providers.
“The acquisition of CardioLabs sets AliveCor on a course to becoming the premier provider of end-to-end cardiac diagnostic support,” said Priya Abani, CEO, AliveCor. “We are creating new opportunities for healthcare providers and patients through enhanced, reimbursed cardiac monitoring services and access to real-time data that helps inform clinical decision-making.”
With the acquisition, AliveCor now manages CardioLabs’ U.S.-based healthcare provider customers and plans to expand the service to new customers in the coming months. Existing CardioLabs customers will retain access to the full suite of cardiac monitoring services previously available to them including Mobile Cardiac Telemetry, Cardiac Event Monitoring, Extended Holter and Holter monitoring. Longer-term, AliveCor’s KardiaMobile 6L will be made available to CardioLabs customers as the world’s first and only wireless, patchless, six-lead cardiac monitor.